Review Article
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update
Table 1
Case reports of conversion to everolimus for Kaposi’s sarcoma after solid organ transplantation.
| | | Age (years)/type of tx | Location of KS | Time post-tx to switch to everolimus, months | Original IS regimen | Everolimus-based IS regimen | Other intervention for KS | Follow-up (months) | Outcome for KS |
| | Campistol and Schena 2007 [52] | 29/kidney | Skin
Lung
Stomach | 24 | CsA
MMF
Steroids | Everolimus
Steroids | Doxorubicin | 5 | Resolution in all locations |
| | Campistol and Schena 2007 [52] | 66/kidney | Skin | 3 | CsA
MMF
Steroids | Everolimus
Steroids | None | 4 | Resolution |
| | Campistol and Schena 2007 [52] | 66/kidney | Not stated | 15 | Tacrolimus
MMF
Steroids | Everolimus
MMF
Steroids | None | 4 | Resolution |
| | Basu et al. 2011 [55] | 55/kidney | Skin
Soft palate | 6 | CsA
Azathioprine
Steroids | Everolimus
Steroids | Leflunomide | 36 | Resolution |
| | Detroyer et al. 2015 [56] | 27/kidney | Skin
Liver
Lymph nodes | 12 | Tacrolimus
MMF
Steroids | Everolimus
Steroids | None | 9 | Resolution at all locations |
| | Lund et al, 2013 [57] | 60/lung | Jejunum/ileum | 18 | CsA
MMF
Steroids | Everolimus
Low CsA
Steroids | None | 12 | Resolution |
|
|
CsA, cyclosporine; IS, immunosuppressive; KS, Kaposi’s sarcoma; MMF, mycophenolate mofetil; tx, transplantation.
|
